schliessen

Filtern

 

Bibliotheken

Immunogenicity of allogeneic mesenchymal stem cells

Mesenchymal stem cells (MSCs) inhibit proliferation of allogeneic T cells and express low levels of major histocompatibility complex class I (MHCI), MHCII and vascular adhesion molecule-1 (VCAM-1). We investigated whether their immunosuppressive properties and low immunophenotype protect allogeneic... Full description

Journal Title: Schu Sabine; Nosov, Mikhail; O'Flynn, Lisa; Shaw, Georgina; Treacy, Oliver; Barry, Frank; Murphy, Mary; O'Brien, Timothy; Ritter, Thomas (2012). Immunogenicity of allogeneic mesenchymal stem cells. Journal of Cellular and Molecular Medicine 16 (9), 2094-2103
Main Author: Schu, Sabine
Other Authors: Nosov, Mikhail , O'Flynn, Lisa , Shaw, Georgina , Treacy, Oliver , Barry, Frank , Murphy, Mary , O'Brien, Timothy , Ritter, Thomas
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 1582-1838 ; DOI: 10.1111/j.1582-4934.2011.01509.x
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: aran10379/13837
title: Immunogenicity of allogeneic mesenchymal stem cells
format: Article
creator:
  • Schu, Sabine
  • Nosov, Mikhail
  • O'Flynn, Lisa
  • Shaw, Georgina
  • Treacy, Oliver
  • Barry, Frank
  • Murphy, Mary
  • O'Brien, Timothy
  • Ritter, Thomas
subjects:
  • Mesenchymal Stem Cells
  • Allo-Antibody
  • Complement
  • Immunogenicity
  • Acute Myocardial-Infarction
  • Proliferation In-Vitro
  • Marrow Stromal Cells
  • Versus-Host-Disease
  • Acute-Renal-Failure
  • Immune-Response
  • Cardiac Allograft
  • Gene-Therapy
  • Nitric-Oxide
  • Calf Serum
ispartof: Schu, Sabine; Nosov, Mikhail; O'Flynn, Lisa; Shaw, Georgina; Treacy, Oliver; Barry, Frank; Murphy, Mary; O'Brien, Timothy; Ritter, Thomas (2012). Immunogenicity of allogeneic mesenchymal stem cells. Journal of Cellular and Molecular Medicine 16 (9), 2094-2103
description: Mesenchymal stem cells (MSCs) inhibit proliferation of allogeneic T cells and express low levels of major histocompatibility complex class I (MHCI), MHCII and vascular adhesion molecule-1 (VCAM-1). We investigated whether their immunosuppressive properties and low immunophenotype protect allogeneic rat MSCs against cytotoxic lysis in vitro and result in a reduced immune response in vivo. Rat MSCs were partially protected against alloantigen-specific cytotoxic T cells in vitro. However, after treatment with IFN-? and IL-1 beta, MSCs upregulated MHCI, MHCII and VCAM-1, and cytotoxic lysis was significantly increased. In vivo, allogeneic T cells but not allogeneic MSCs induced upregulation of the activation markers CD25 and CD71 as well as downregulation of CD62L on CD4+ T cells from recipient rats. However, intravenous injection of allo-MSCs in rats led to the formation of alloantibodies with the capacity to facilitate complement-mediated lysis, although IgM levels were markedly decreased compared with animals that received T cells. The allo-MSC induced immune response was sufficient to lead to significantly reduced survival of subsequently injected allo-MSCs. Interestingly, no increased immunogenicity of IFN-? stimulated allo-MSCs was observed in vivo. Both the loss of protection against cytotoxic lysis under inflammatory conditions and the induction of complement-activating antibodies will likely impact the utility of allogeneic MSCs for therapeutic applications.
language:
source:
identifier: ISSN: 1582-1838 ; DOI: 10.1111/j.1582-4934.2011.01509.x
fulltext: fulltext_linktorsrc
issn:
  • 15821838
  • 1582-1838
url: Link


@attributes
ID1740701099
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10379/13837
sourceidaran
recordidTN_aran10379/13837
sourcesystemOther
pqid1035102051
galeid310582466
display
typearticle
titleImmunogenicity of allogeneic mesenchymal stem cells
creatorSchu, Sabine ; Nosov, Mikhail ; O'Flynn, Lisa ; Shaw, Georgina ; Treacy, Oliver ; Barry, Frank ; Murphy, Mary ; O'Brien, Timothy ; Ritter, Thomas
ispartofSchu, Sabine; Nosov, Mikhail; O'Flynn, Lisa; Shaw, Georgina; Treacy, Oliver; Barry, Frank; Murphy, Mary; O'Brien, Timothy; Ritter, Thomas (2012). Immunogenicity of allogeneic mesenchymal stem cells. Journal of Cellular and Molecular Medicine 16 (9), 2094-2103
identifier ISSN: 1582-1838 ; DOI: 10.1111/j.1582-4934.2011.01509.x
subjectMesenchymal Stem Cells ; Allo-Antibody ; Complement ; Immunogenicity ; Acute Myocardial-Infarction ; Proliferation In-Vitro ; Marrow Stromal Cells ; Versus-Host-Disease ; Acute-Renal-Failure ; Immune-Response ; Cardiac Allograft ; Gene-Therapy ; Nitric-Oxide ; Calf Serum
descriptionMesenchymal stem cells (MSCs) inhibit proliferation of allogeneic T cells and express low levels of major histocompatibility complex class I (MHCI), MHCII and vascular adhesion molecule-1 (VCAM-1). We investigated whether their immunosuppressive properties and low immunophenotype protect allogeneic rat MSCs against cytotoxic lysis in vitro and result in a reduced immune response in vivo. Rat MSCs were partially protected against alloantigen-specific cytotoxic T cells in vitro. However, after treatment with IFN-? and IL-1 beta, MSCs upregulated MHCI, MHCII and VCAM-1, and cytotoxic lysis was significantly increased. In vivo, allogeneic T cells but not allogeneic MSCs induced upregulation of the activation markers CD25 and CD71 as well as downregulation of CD62L on CD4+ T cells from recipient rats. However, intravenous injection of allo-MSCs in rats led to the formation of alloantibodies with the capacity to facilitate complement-mediated lysis, although IgM levels were markedly decreased compared with animals that received T cells. The allo-MSC induced immune response was sufficient to lead to significantly reduced survival of subsequently injected allo-MSCs. Interestingly, no increased immunogenicity of IFN-? stimulated allo-MSCs was observed in vivo. Both the loss of protection against cytotoxic lysis under inflammatory conditions and the induction of complement-activating antibodies will likely impact the utility of allogeneic MSCs for therapeutic applications.
source
version9
oafree_for_read
lds50peer_reviewed
links
openurl$$Topenurl_article
linktorsrc$$Uhttp://hdl.handle.net/10379/13837$$EView_full_text_in_the_National_University_of_Ireland_Galway
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Schu, Sabine
1Nosov, Mikhail
2O'Flynn, Lisa
3Shaw, Georgina
4Treacy, Oliver
5Barry, Frank
6Murphy, Mary
7O'Brien, Timothy
8Ritter, Thomas
titleImmunogenicity of allogeneic mesenchymal stem cells
descriptionMesenchymal stem cells (MSCs) inhibit proliferation of allogeneic T cells and express low levels of major histocompatibility complex class I (MHCI), MHCII and vascular adhesion molecule-1 (VCAM-1). We investigated whether their immunosuppressive properties and low immunophenotype protect allogeneic rat MSCs against cytotoxic lysis in vitro and result in a reduced immune response in vivo. Rat MSCs were partially protected against alloantigen-specific cytotoxic T cells in vitro. However, after treatment with IFN-? and IL-1 beta, MSCs upregulated MHCI, MHCII and VCAM-1, and cytotoxic lysis was significantly increased. In vivo, allogeneic T cells but not allogeneic MSCs induced upregulation of the activation markers CD25 and CD71 as well as downregulation of CD62L on CD4+ T cells from recipient rats. However, intravenous injection of allo-MSCs in rats led to the formation of alloantibodies with the capacity to facilitate complement-mediated lysis, although IgM levels were markedly decreased compared with animals that received T cells. The allo-MSC induced immune response was sufficient to lead to significantly reduced survival of subsequently injected allo-MSCs. Interestingly, no increased immunogenicity of IFN-? stimulated allo-MSCs was observed in vivo. Both the loss of protection against cytotoxic lysis under inflammatory conditions and the induction of complement-activating antibodies will likely impact the utility of allogeneic MSCs for therapeutic applications.
subject
0Mesenchymal Stem Cells
1Allo-Antibody
2Complement
3Immunogenicity
4Acute Myocardial-Infarction
5Proliferation In-Vitro
6Marrow Stromal Cells
7Versus-Host-Disease
8Acute-Renal-Failure
9Immune-Response
10Cardiac Allograft
11Gene-Therapy
12Nitric-Oxide
13Calf Serum
general
0Wiley-Blackwell
1Schu, Sabine; Nosov, Mikhail; O'Flynn, Lisa; Shaw, Georgina; Treacy, Oliver; Barry, Frank; Murphy, Mary; O'Brien, Timothy; Ritter, Thomas (2012). Immunogenicity of allogeneic mesenchymal stem cells. Journal of Cellular and Molecular Medicine 16 (9), 2094-2103
210.1111/j.1582-4934.2011.01509.x
3Article
4National University of Ireland Galway
5ARAN (National University of Ireland Galway)
sourceidaran
recordidaran10379/13837
rsrctypearticle
creationdate2012
addtitleSchu, Sabine; Nosov, Mikhail; O'Flynn, Lisa; Shaw, Georgina; Treacy, Oliver; Barry, Frank; Murphy, Mary; O'Brien, Timothy; Ritter, Thomas (2012). Immunogenicity of allogeneic mesenchymal stem cells. Journal of Cellular and Molecular Medicine 16 (9), 2094-2103
searchscopearan
scopearan
issn
015821838
11582-1838
lsr30VSR-Enriched:[issue, pages, vol, galeid, eissn, pqid]
sort
titleImmunogenicity of allogeneic mesenchymal stem cells
authorSchu, Sabine ; Nosov, Mikhail ; O'Flynn, Lisa ; Shaw, Georgina ; Treacy, Oliver ; Barry, Frank ; Murphy, Mary ; O'Brien, Timothy ; Ritter, Thomas
creationdate20120823
facets
frbrgroupid4794311868301716334
frbrtype5
newrecords20180925
creationdate2012
topic
0Mesenchymal Stem Cells
1Allo-Antibody
2Complement
3Immunogenicity
4Acute Myocardial-Infarction
5Proliferation In-Vitro
6Marrow Stromal Cells
7Versus-Host-Disease
8Acute-Renal-Failure
9Immune-Response
10Cardiac Allograft
11Gene-Therapy
12Nitric-Oxide
13Calf Serum
collectionARAN (National University of Ireland Galway)
prefilterarticles
rsrctypearticles
creatorcontrib
0Schu, Sabine
1Nosov, Mikhail
2O'Flynn, Lisa
3Shaw, Georgina
4Treacy, Oliver
5Barry, Frank
6Murphy, Mary
7O'Brien, Timothy
8Ritter, Thomas
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
aulast
0Schu
1Nosov
2O'Flynn
3Shaw
4Treacy
5Barry
6Murphy
7O'Brien
8Ritter
aufirst
0Sabine
1Mikhail
2Lisa
3Georgina
4Oliver
5Frank
6Mary
7Timothy
8Thomas
au
0Schu, Sabine
1Nosov, Mikhail
2O'Flynn, Lisa
3Shaw, Georgina
4Treacy, Oliver
5Barry, Frank
6Murphy, Mary
7O'Brien, Timothy
8Ritter, Thomas
atitleImmunogenicity of allogeneic mesenchymal stem cells
risdate20120823
issn1582-1838
genrearticle
ristypeJOUR
abstractMesenchymal stem cells (MSCs) inhibit proliferation of allogeneic T cells and express low levels of major histocompatibility complex class I (MHCI), MHCII and vascular adhesion molecule-1 (VCAM-1). We investigated whether their immunosuppressive properties and low immunophenotype protect allogeneic rat MSCs against cytotoxic lysis in vitro and result in a reduced immune response in vivo. Rat MSCs were partially protected against alloantigen-specific cytotoxic T cells in vitro. However, after treatment with IFN-? and IL-1 beta, MSCs upregulated MHCI, MHCII and VCAM-1, and cytotoxic lysis was significantly increased. In vivo, allogeneic T cells but not allogeneic MSCs induced upregulation of the activation markers CD25 and CD71 as well as downregulation of CD62L on CD4+ T cells from recipient rats. However, intravenous injection of allo-MSCs in rats led to the formation of alloantibodies with the capacity to facilitate complement-mediated lysis, although IgM levels were markedly decreased compared with animals that received T cells. The allo-MSC induced immune response was sufficient to lead to significantly reduced survival of subsequently injected allo-MSCs. Interestingly, no increased immunogenicity of IFN-? stimulated allo-MSCs was observed in vivo. Both the loss of protection against cytotoxic lysis under inflammatory conditions and the induction of complement-activating antibodies will likely impact the utility of allogeneic MSCs for therapeutic applications.
pubWiley-Blackwell
doi10.1111/j.1582-4934.2011.01509.x
urlhttp://hdl.handle.net/10379/13837
formatarticle
issue9
pages2094-2094103
volume16
eissn15824934
oafree_for_read
date2012-08-23